Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | SMPD1 | P17405 | 8/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Falipamil SCHEMBL30357974 | 1.00 | MAPT (0.68) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| Falipamil SCHEMBL31305297 | 1.00 | MAPT (0.68) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| SCHEMBL25861789 | 0.92 | MAPT (0.58) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| SCHEMBL10979064 | 0.89 | HCN4 (0.78) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| Hydrochloric Acid SCHEMBL11535889 | 0.89 | CYP3A4 (0.78) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| SCHEMBL10981924 | 0.88 | HCN4 (0.69) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| Hydrochloric Acid SCHEMBL10981695 | 0.87 | CYP3A4 (0.69) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| SCHEMBL9624425 | 0.85 | HCN4 (0.51) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| SCHEMBL9624484 | 0.85 | HCN4 (0.51) | MAPTHCN4CYP3A4ALOX15CYP1A2 | |
| Hydrochloric Acid SCHEMBL9624321 | 0.85 | CYP3A4 (0.52) | MAPTHCN4CYP3A4ALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124180-A1 | METHOD OF TREATING AFFECTIVE DISORDERS AND PERSONALITY DISORDERS | HB BIOTECH, INC. (US) | 2026-05-07 | — | — | US | claimed |
| EP-4724060-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB Biotech, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12539291-B2 | Method of treating affective disorders and personality disorders | HB BIOTECH, INC. (US) | 2026-02-03 | — | — | US | claimed |
| US-20260028594-A1 | CELL PATCH CRYOPRESERVATION SOLUTION AND METHOD OF CRYOPRESERVING A CELL PATCH | BOE REGENERATIVE MEDICINE TECH CO LTD (CN) | 2026-01-29 | — | — | US | claimed |
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | claimed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| WO-2024254389-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB BIOTECH, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-12128031-B2 | Method of improving psychosocial health | HB BIOTECH, INC. (US) | 2024-10-29 | — | — | US | claimed |
| WO-2024216594-A1 | CELL SHEET CRYOPRESERVATION SOLUTION AND METHOD FOR CRYOPRESERVING CELL SHEET | 京东方科技集团股份有限公司 | 2024-10-24 | — | — | WO | claimed |
| EP-4337675-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Universidad De Chile (CL) | 2024-03-20 | — | — | EP | claimed |
| EP-0312291-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312157-A2 | Tetrapeptide renin inhibitors having a novel c-terminal amino acid | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312158-A2 | Tetrapeptide renin inhibitors having novel c-terminal amino acid amide | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0312283-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | claimed |
| US-4782043-A | HYPOTENSIVES | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| US-4584294-A | Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents | MERCK & CO., INC. (US) | 1986-04-22 | — | — | US | claimed |
| EP-0166353-A2 | Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028594-A1 | CELL PATCH CRYOPRESERVATION SOLUTION AND METHOD OF CRYOPRESERVING A CELL PATCH | BCL2, CACNA1I, BAX | MAPT 2725/4885HCN4 227/4885CYP3A4 2468/4885 |
| US-12128031-B2 | Method of improving psychosocial health | DBH, TPH2, TPH1 | MAPT 1218/4885HCN4 1453/4885CYP3A4 4300/4885 |
| US-12539291-B2 | Method of treating affective disorders and personality disorders | HTR1D, HTR1A, HTR4 | MAPT 242/4885HCN4 737/4885CYP3A4 325/4885 |
| US-20260124180-A1 | METHOD OF TREATING AFFECTIVE DISORDERS AND PERSONALITY DISORDERS | HTR1D, HTR4, HTR1A | MAPT 330/4885HCN4 740/4885CYP3A4 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.